Your browser doesn't support javascript.
loading
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
Bachelot, Thomas; Filleron, Thomas; Bieche, Ivan; Arnedos, Monica; Campone, Mario; Dalenc, Florence; Coussy, Florence; Sablin, Marie-Paule; Debled, Marc; Lefeuvre-Plesse, Claudia; Goncalves, Anthony; Reynier, Marie-Ange Mouret; Jacot, William; You, Benoit; Barthelemy, Philippe; Verret, Benjamin; Isambert, Nicolas; Tchiknavorian, Xavier; Levy, Christelle; Thery, Jean-Christophe; L'Haridon, Tifenn; Ferrero, Jean-Marc; Mege, Alice; Del Piano, Francesco; Rouleau, Etienne; Tran-Dien, Alicia; Adam, Julien; Lusque, Amelie; Jimenez, Marta; Jacquet, Alexandra; Garberis, Ingrid; Andre, Fabrice.
Afiliação
  • Bachelot T; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Filleron T; Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.
  • Bieche I; Department of Genetics, Institut Curie and Paris-Descartes University, Paris, France.
  • Arnedos M; Department of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Campone M; Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain et Angers, France.
  • Dalenc F; Department of Medical Oncology, Institut Claudius-Regaud, IUCT Oncopole and University of Paul Sabatier, Toulouse, France.
  • Coussy F; Department of Medical Oncology, Institut Curie, Paris, France.
  • Sablin MP; Department of Medical Oncology, Institut Curie, Paris, France.
  • Debled M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Lefeuvre-Plesse C; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Reynier MM; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
  • Jacot W; Department of Medical Oncology, Institut de Cancérologie de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194 and Montpellier Université, Montpellier, France.
  • You B; Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL); Centre d'Investigation de Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL); Univ Lyon, Université Claude Bernard Lyon 1; EMR UCBL/HCL 3738; GINECO, Lyon, France.
  • Barthelemy P; Centre Hospitalier Lyon Sud, Pierre Bénite, France.
  • Verret B; Institut de Cancérologie Strasbourg, Strasbourg, France.
  • Isambert N; Hôpitaux Universitaire de Strasbourg, Strasbourg, France.
  • Tchiknavorian X; Department of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Levy C; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Thery JC; Centre Hospitalier Intercommunal Toulon La Seyne-sur-Mer, Hôpital Sainte Musse, Toulon, France.
  • L'Haridon T; Department of Medical Oncology, Centre François Baclesse, Caen, France.
  • Ferrero JM; Department of Medical Oncology, Centre Henri Becquerel, University of Medicine of Rouen, Rouen, France.
  • Mege A; Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.
  • Del Piano F; Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
  • Rouleau E; Institut Sainte Catherine, Avignon, France.
  • Tran-Dien A; Hôpitaux du Leman, Thonon Les Bains, France.
  • Adam J; Cancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Lusque A; INSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Jimenez M; Université Paris Saclay, Le Kremlin-Bicetre, France.
  • Jacquet A; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Garberis I; INSERM U1186, Gustave Roussy Cancer Campus, Villejuif, France.
  • Andre F; Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.
Nat Med ; 27(2): 250-255, 2021 02.
Article em En | MEDLINE | ID: mdl-33462450
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Mama Triplo Negativas / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Mama Triplo Negativas / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França